Risk factors for neuroendocrine neoplasms: A systematic review and meta-analysis

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 68-81

  Leoncini, E ^a   Carioli, G ^b   La Vecchia, C ^b   Boccia, S ^a   Rindi, Guido ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Digestive tract; Lung; Neuroendocrine neoplasms; Risk factors

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ALCOHOL CONSUMPTION; APPENDICEAL NEUROENDOCRINE NEOPLASM; APPENDIX CANCER; ARTICLE; BLOOD PRESSURE; BODY MASS; BRAIN CANCER; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CHOLECYSTECTOMY; COHORT ANALYSIS; COLON CANCER; COLON NEUROENDOCRINE NEOPLASM; COLONOSCOPY; COLORECTAL CANCER; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRINKING BEHAVIOR; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FAT INTAKE; FATTY LIVER; FIRST DEGREE RELATIVE; GALLBLADDER CANCER; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; HUMAN; IL1B GENE; INSULIN RESISTANCE; KIDNEY CANCER; LUNG CANCER; LUNG NEUROENDOCRINE NEOPLASM; MEAT; METABOLIC SYNDROME X; MOUTH CANCER; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREATIC NEUROENDOCRINE TUMOR; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROSTATE CANCER; RECTAL NEUROENDOCRINE NEOPLASM; RECTUM CANCER; SARCOMA; SECOND DEGREE RELATIVE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; SMALL INTESTINAL NEUROENDOCRINE NEOPLASM; SMALL INTESTINE CANCER; SMOKING; STANDARDIZATION; STOMACH CANCER; SYSTEMATIC REVIEW; ADVERSE EFFECTS; COMPLICATION; DIGESTIVE SYSTEM NEOPLASMS; LUNG NEOPLASMS; META ANALYSIS; NEUROENDOCRINE TUMORS; OBESITY; RISK FACTOR;

ALCOHOL DRINKING; DIGESTIVE SYSTEM NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; OBESITY; RISK FACTORS; SMOKING;

EID: 84960124039     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv505     Document Type: Article

References (54)

1. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid':epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
2. SEER. Surveillance, Epidemiology, and End Results Program. 2014; http://www. seer.cancer.gov (15 December 2014, date last accessed).
3. Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology:contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
4. Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade:experience of two decades of cancer registry. Eur J Cancer 2013; 49: 1975-1983.
5. Tsai HJ, Wu CC, Tsai CR et al. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS ONE 2013; 8: e62487.
6. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813-829.
7. Levi F, Te VC, Randimbison L et al. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer 2000; 83: 952-955.
8. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92: 2204-2210.
9. Caldarella A, Crocetti E, Paci E. Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res 2011; 17: 759-763.
10. Luke C, Price T, Townsend A et al. Epidemiology of neuroendocrine cancers in an Australian population. Cancer Causes Control 2010; 21: 931-938.
11. Hassan MM, Phan A, Li D et al. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer 2008; 123: 867-873.
12. Hassan MM, Phan A, Li D et al. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 959-965.
13. Nogueira L, Freedman ND, Engels EA et al. Gallstones, cholecystectomy, and risk of digestive system cancers. Am J Epidemiol 2014; 179: 731-739.
14. Ter-Minassian M, Wang Z, Asomaning K et al. Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis 2011; 32: 1216-1222.
15. Halfdanarson TR, Bamlet WR, McWilliams RR et al. Risk factors for pancreatic neuroendocrine tumors a clinic-based case-control study. Pancreas 2014; 43: 1219-1222.
16. Chen CC, Neugut AI, Rotterdam H. Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings. Cancer Epidemiol Biomarkers Prev 1994; 3: 205-207.
17. Cigrovski Berkovic M, Catela Ivkovic T, Marout J et al. Interleukin 1beta gene single-nucleotide polymorphisms and susceptibility to pancreatic neuroendocrine tumors. DNA Cell Biol 2012; 31: 531-536.
18. Kaerlev L, Teglbjaerg PS, Sabroe S et al. The importance of smoking and medical history for development of small bowel carcinoid tumor: a European populationbased case-control study. Cancer Causes Control 2002; 13: 27-34.
19. Kaerlev L, Teglbjaerg PS, Sabroe S et al. Occupational risk factors for small bowel carcinoid tumor: a European population-based case-control study. J Occup Environ Med 2002; 44: 516-522.
20. Capurso G, Falconi M, Panzuto F et al. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am J Gastroenterol 2009; 104: 3034-3041.
21. Karakaxas D, Gazouli M, Coker A et al. Genetic polymorphisms of inflammatory response gene TNF-alpha and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk. Med Oncol 2014; 31: 241.
22. Berkovic M, Cacev T, Zjacic-Rotkvic V, Kapitanovic S. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2006; 84: 346-352.
23. Burnik FS, Yalcin S. NFKB1-94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009; 55: 381-385.
24. Haugvik SP, Hedenstrom P, Korsaeth E et al. Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Neuroendocrinology 2015; 101: 133-142.
25. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
26. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/ programs/clinical_epidemiology/oxford.asp (15 December 2014, date last accessed).
27. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses. Stat Med 2010; 29: 1282-1297.
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
29. Cross AJ, Leitzmann MF, Subar AF et al. A prospective study of meat and fat intake in relation to small intestinal cancer. Cancer Res 2008; 68: 9274-9279.
30. Cross AJ, Hollenbeck AR, Park Y. A large prospective study of risk factors for adenocarcinomas and malignant carcinoid tumors of the small intestine. Cancer Causes Control 2013; 24: 1737-1746.
31. Kharazmi E, Pukkala E, Sundquist K, Hemminki K. Familial risk of small intestinal carcinoid and adenocarcinoma. Clin Gastroenterol Hepatol 2013; 11: 944-949.
32. Amin S, Warner RRP, Itzkowitz SH, Kim MK. The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study. Endocr Relat Cancer 2012; 19: 381-387.
33. Hemminki K, Li X. Familial carcinoid tumors and subsequent cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2001; 94: 444-448.
34. Kamp K, Damhuis RAM, Feelders RA, de Herder WW. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. Endocr Relat Cancer 2012; 19: 95-99.
35. Hiripi E, Bermejo JL, Sundquist J, Hemminki K. Familial gastrointestinal carcinoid tumours and associated cancers. Ann Oncol 2009; 20: 950-954.
36. Zhan HX, Cong L, Zhao YP et al. Risk factors for the occurrence of insulinoma: a case-control study. Hepatobiliary Pancreat Dis Int 2013; 12: 324-328.
37. Lu Y, Lambe M, Martling A, Lagergren J. Reproductive history and risk of small bowel cancer by histologic type: a population-based study. Cancer Causes Control 2012; 23: 2041-2046.
38. Jung YS, Yun KE, Chang Y et al. Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study. Cancer Epidemiol Biomarkers Prev 2014; 23: 1406-1413.
39. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.
40. Rindi G, Falconi M, Klersy C et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012; 104: 764-777.
41. Hallet J, Law CH, Cukier M et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121: 589-597.
42. Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 2000; 75: 310-316.
43. Perez EA, Koniaris LG, Snell SE et al. 7201 carcinoids: increasing incidence overall and disproportionate mortality in the elderly. World J Surg 2007; 31: 1022-1030.
44. Zar N, Garmo H, Holmberg L, Hellman P. Risk of second primary malignancies and causes of death in patients with adenocarcinoma and carcinoid of the small intestine. Eur J Cancer 2008; 44: 718-725.
45. Landerholm K, Zar N, Andersson RE et al. Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 2011; 98: 1617-1624.
46. Scherubl H, Streller B, Stabenow R et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 2013; 19: 9012-9019.
47. Ohtani N, Yoshimoto S, Hara E. Obesity and cancer: a gut microbial connection. Cancer Res 2014; 74: 1885-1889.
48. Tsuei J, Chau T, Mills D, Wan YJ. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood) 2014; 239: 1489-1504.
49. International Agency for Research on Cancer. List of classifications by cancer sites with sufficient or limited evidence in humans. Volumes 1 to 112*.
50. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-1937.
51. Elena JW, Steplowski E, Yu K et al. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 2013; 24: 13-25.
52. Batabyal P, Vander Hoorn S, Christophi C, Nikfarjam M. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol 2014; 21: 2453-2462.
53. Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes (Lond) 2008; 32(Suppl 3): S56-S59.
54. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR, 2007.